Morgan Stanley analysts Sean Laaman and Maxwell Skor have identified three significant biotech breakthroughs that could reshape investor returns across multiple sectors. According to reports from Morgan Stanley, these breakthroughs span Alzheimer's drugs, gene editing, and artificial intelligence (AI) technologies. The research was presented during the bank's annual Global Healthcare Conference in New York, highlighting the potential for multibillion-dollar market opportunities.
Morgan Stanley sizes the Alzheimer's drug market at $70 billion, dividing it between therapies that slow cognitive decline and treatments for symptoms such as psychosis and agitation. As reported by Morgan Stanley, the bank sees significant upside beyond traditional drugmakers, with delaying nursing home entry by 12 to 18 months delivering US healthcare value worth multiples of list price. This creates potential opportunities for diagnostics, care delivery, retirement, and insurance firms that could benefit or need to adapt to these developments.
The report highlights the evolution from early gene-editing therapies that worked ex vivo to in-vivo versions that edit DNA inside the body. According to Morgan Stanley's forecast, the bank projects a $10 billion in-vivo market by 2035 in near-term indications, significantly higher than consensus estimates of $6 billion. Data expected over the next 18 months could determine how investors value these platforms and their potential market penetration.
Morgan Stanley estimates that AI could cut drug discovery timelines from about 4.5 years to 1.5 years and lower research and development costs by 25% to 60%. However, as reported by the bank, there is little proof that AI raises the odds of a drug reaching patients. Therefore, Morgan Stanley prefers companies that supply data, tools, and computing power rather than drug developers, as these businesses convert adoption into revenue and rely less on binary clinical outcomes.
According to Morgan Stanley strategist Mike Wilson, clinical data can still swing biotech shares sharply, as demonstrated by Moderna's August rally following late-stage cancer vaccine results. The report warns of potential market corrections within 30 days if oil prices spike and drain liquidity. Morgan Stanley suggests that the most actionable exposure sits furthest from the lab, while the biggest upside awaits data, emphasizing the importance of timing and regulatory developments in these emerging biotech sectors.
